芦可替尼治疗慢性中性粒细胞白血病与非典型慢性髓性白血病的II期研究
该II期研究评估JAK1/2抑制剂芦可替尼在44例慢性中性粒细胞白血病(CNL)和非典型慢性髓性白血病(aCML)患者中的安全性和疗效,不限CSF3R突变状态。前25例可评估患者总缓解率32%,全组35%缓解,CNL及CSF3R-T618I突变者更易缓解,耐受性良好。
要点
- 芦可替尼在CNL/aCML中总缓解率约32%-35%,CNL及CSF3R-T618I突变者应答更优。
- 3级及以上贫血和血小板减少发生率分别为34%和14%,无芦可替尼相关严重不良事件。
- 常见死亡原因为疾病进展。
核心结论
- 芦可替尼耐受性良好,估计缓解率为32%。
- 诊断为CNL和/或携带CSF3R-T618I的患者最可能获得缓解。
研究设计与样本
- II期研究,纳入44例CNL(21例)和aCML(23例)患者,不限CSF3R突变状态。
- 主要终点为前25例患者连续6个28天周期结束时的总体血液学缓解率(ORR),缓解包括部分缓解(PR)和完全缓解(CR)。
主要发现
- 前25例入组患者ORR为32%(8例PR:7例CNL和1例aCML)。
- 在44例扩大队列中,35%的患者有缓解(11例PR:9例CNL和2例aCML;4例CR:CNL),50%携带致癌性CSF3R突变。
- 6周期后CSF3R-T618I平均绝对等位基因负荷减少在CR组最大,优于PR组和无缓解组。
- 最常见死亡原因为疾病进展。
- ≥3级贫血和血小板减少分别见于34%和14%的患者,未观察到归因于芦可替尼的严重不良事件。
临床怎么用
- 对于CNL和aCML患者,尤其CNL或携带CSF3R-T618I者,芦可替尼可作为治疗选择。
- 治疗期间需监测贫血和血小板减少等血液学毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS: We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML). The primary end point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the first 25 patients enrolled. We considered a response as either partial (PR) or complete response (CR). We expanded accrual to 44 patients to increase our ability to evaluate secondary end points, including grade ≥ 3 adverse events, spleen volume, symptom assessment, genetic correlates of response, and 2-year survival. RESULTS: ORR was 32% for the first 25 enrolled patients (8 PR [7 CNL and 1 aCML]). In the larger cohort of 44 patients, 35% had a response (11 PR [9 CNL and 2 aCML] and 4 CR [CNL]), and 50% had oncogenic CSF3R mutations. The mean absolute allele burden reduction of CSF3R-T618I after 6 cycles was greatest in the CR group, compared with the PR and no response groups. The most common cause of death is due to disease progression. Grade ≥ 3 anemia and thrombocytopenia were observed in 34% and 14% of patients, respectively. No serious adverse events attributed to ruxolitinib were observed. CONCLUSION: Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.
引用
- Dao KT, Gotlib J, Deininger MMN, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2019. PMID: 31880950. doi:10.1200/JCO.19.00895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。